Repligen Corp has a consensus price target of $195.54, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Stifel, Keybanc, and JP Morgan on February 22, 2024, February 15, 2024, and December 20, 2023. With an average price target of $212.33 between Stifel, Keybanc, and JP Morgan, there's an implied 15.45% upside for Repligen Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/22/2024 | RGEN | Buy Now | Repligen | $183.92 | 12.55% | Stifel | Daniel Arias | $165 → $207 | Maintains | Buy | Get Alert |
02/15/2024 | RGEN | Buy Now | Repligen | $183.92 | 19.62% | Keybanc | Paul Knight | $210 → $220 | Maintains | Overweight | Get Alert |
12/20/2023 | RGEN | Buy Now | Repligen | $183.92 | 14.18% | JP Morgan | Tycho Peterson | $170 → $210 | Maintains | Overweight | Get Alert |
12/04/2023 | RGEN | Buy Now | Repligen | $183.92 | — | Benchmark | Robert Wasserman | — | Downgrade | Buy → Hold | Get Alert |
11/02/2023 | RGEN | Buy Now | Repligen | $183.92 | -7.57% | UBS | Elizabeth Garcia | $210 → $170 | Maintains | Buy | Get Alert |
11/01/2023 | RGEN | Buy Now | Repligen | $183.92 | -10.29% | Stifel | Daniel Arias | $200 → $165 | Maintains | Buy | Get Alert |
11/01/2023 | RGEN | Buy Now | Repligen | $183.92 | 8.74% | RBC Capital | Conor McNamara | $207 → $200 | Maintains | Outperform | Get Alert |
11/01/2023 | RGEN | Buy Now | Repligen | $183.92 | 14.18% | Keybanc | Paul Knight | $240 → $210 | Maintains | Overweight | Get Alert |
10/17/2023 | RGEN | Buy Now | Repligen | $183.92 | -2.13% | JP Morgan | Tycho Peterson | $200 → $180 | Maintains | Overweight | Get Alert |
09/08/2023 | RGEN | Buy Now | Repligen | $183.92 | 3.85% | RBC Capital | Conor McNamara | → $191 | Reiterates | Outperform → Outperform | Get Alert |
09/06/2023 | RGEN | Buy Now | Repligen | $183.92 | 3.85% | RBC Capital | Conor McNamara | → $191 | Reiterates | Outperform → Outperform | Get Alert |
08/03/2023 | RGEN | Buy Now | Repligen | $183.92 | 8.74% | Craig-Hallum | Matt Hewitt | $207 → $200 | Maintains | Buy | Get Alert |
08/03/2023 | RGEN | Buy Now | Repligen | $183.92 | 6.02% | RBC Capital | Conor McNamara | $157 → $195 | Maintains | Outperform | Get Alert |
08/03/2023 | RGEN | Buy Now | Repligen | $183.92 | 8.74% | Stephens & Co. | Jacob Johnson | $180 → $200 | Maintains | Overweight | Get Alert |
07/20/2023 | RGEN | Buy Now | Repligen | $183.92 | 0.59% | Wells Fargo | Timothy Daley | → $185 | Initiates | → Overweight | Get Alert |
07/06/2023 | RGEN | Buy Now | Repligen | $183.92 | -15.18% | RBC Capital | Conor McNamara | → $156 | Upgrade | Sector Perform → Outperform | Get Alert |
05/03/2023 | RGEN | Buy Now | Repligen | $183.92 | -14.64% | RBC Capital | Conor McNamara | $170 → $157 | Maintains | Sector Perform | Get Alert |
05/03/2023 | RGEN | Buy Now | Repligen | $183.92 | 14.18% | Stifel | Daniel Arias | $225 → $210 | Maintains | Buy | Get Alert |
05/03/2023 | RGEN | Buy Now | Repligen | $183.92 | 8.74% | Stephens & Co. | Jacob Johnson | $220 → $200 | Maintains | Overweight | Get Alert |
The latest price target for Repligen (NASDAQ: RGEN) was reported by Stifel on February 22, 2024. The analyst firm set a price target for $207.00 expecting RGEN to rise to within 12 months (a possible 12.55% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for Repligen (NASDAQ: RGEN) was provided by Stifel, and Repligen maintained their buy rating.
The last upgrade for Repligen Corp happened on July 6, 2023 when RBC Capital raised their price target to $156. RBC Capital previously had a sector perform for Repligen Corp.
The last downgrade for Repligen Corp happened on December 4, 2023 when Benchmark changed their price target from N/A to N/A for Repligen Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Repligen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Repligen was filed on February 22, 2024 so you should expect the next rating to be made available sometime around February 22, 2025.
While ratings are subjective and will change, the latest Repligen (RGEN) rating was a maintained with a price target of $165.00 to $207.00. The current price Repligen (RGEN) is trading at is $183.92, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.